Ixekizumab improves patient-reported outcomes in patients with active psoriatic arthritis and inadequate response to tumour necrosis factor inhibitors: SPIRIT-P2 results to 52 weeks

A. Kavanaugh¹, H. Marzo-Ortega², R. Vender³, C.-C. Wei⁴, J. Birt⁵, D.H. Adams⁶, O. Benichou⁶, C.-Y. Lin⁷, P. Nash⁸

¹Division of Rheumatology, Allergy, and Immunology, University of California, San Diego (UCSD) School of Medicine, San Diego, CA, USA; ²NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust and LIRMM, University of Leeds, UK; ³Dermatrials Research, Inc, Hamilton, Ontario, Canada; ⁴Institute of Medicine, Chung Shan Medical University; Chung Shan Medical University Hospital; Graduate Institute of Integrated Medicine, Division of Allergy, Immunology and Rheumatology, China Medical University, Taichung, Taiwan; ⁵Eli Lilly and Company, Global Patient Outcomes and Real World Evidence, Indianapolis, IN, USA; ⁶Eli Lilly and Company, Real-world Analytics-Immunology, Global Statistical Science, Indianapolis, IN, USA; ⁷Department of Medicine, Rheumatology Research Unit, University of Queensland, Sunshine Coast, QLD, Australia.

Abstract

Objective

To report patient-reported outcomes (PROs) of ixekizumab-treated patients with psoriatic arthritis (PsA) and an inadequate response (IR) or intolerance to tumour necrosis factor inhibitors (TNFi) to 52 weeks.

Methods

In SPIRIT-P2, patients with active PsA and an IR or intolerance to TNFi were randomised to ixekizumab 80 mg every 4 weeks (IXEQ4W; N=122) or every 2 weeks (IXEQ2W; N=123), or placebo (PBO; N=118) during the initial 24-week double-blind treatment period. At Week 16, background therapy was modified for IRs; additionally, IRs in the placebo group were re-randomised (1:1) to IXEQ2W or IXEQ4W. Patients receiving ixekizumab at Week 24 received the same dose during the study remainder. Patients completed several PROs for PsA disease activity, skin, health-related quality of life (HRQOL), and work productivity through Week 52.

Results

Ixekizumab-treated patients reported significant improvements versus PBO in 36-Item Short Form Health Survey version 2, European Quality of Life 5 Dimensions visual analogue scale, Bath Ankylosing Spondylitis Disease Activity Index (total score and question 2), and Work Productivity and Activity Impairment Questionnaire-Specific Health Problem (3 of 4 domains) through Week 24. At Week 24, 9% (PBO), 52% (IXEQ4W), and 50% (IXEQ2W) of patients reported Dermatology Life Quality Index scores of 0 or 1; 0% (PBO) and 24% (IXEQ4W and IXEQ2W) reported Itch Numeric Rating Scale score of 0. Where data were collected, improvements persisted through Week 52.

Conclusion

In patients with PsA and an IR or intolerance to TNFi, ixekizumab significantly improved disease activity, skin symptoms, HRQOL, and work productivity to 52 weeks.

Key words

ixekizumab, quality of life, psoriatic arthritis, clinical trial, IL-17
Ixekizumab improves patient-reported outcomes / A. Kavanaugh et al.

Arthur Kavanaugh, MD
Helena Marco-Ortega, MRCP, PhD
Ronald Vender, MD, FRCP
Cheng-Chung Wei, MD, PhD
Julie Birt, PharmD
David H. Adams, PhD
Olivier Benichou, MD
Chen-Yen Lin, PhD
Peter Nash, FRACP
Please address correspondence to:
Dr Arthur Kavanaugh,
9500 Gilman Drive, MC 0943,
La Jolla, CA 92093-0943, USA.
E-mail: akavanaugh@ucsd.edu
Received on April 30, 2018; accepted in revised form on August 27, 2018.
© Copyright CLINICAL AND EXPERIMENTAL RHEUMATOLOGY 2019.

**Funding:** This study was supported by Eli Lilly and Company.

**Competing interests:** A. Kavanaugh reports consulting for Eli Lilly and Company. H. Marco-Ortega received grants from Janssen, and honoraria speaker/consultancy fees from AbbVie, Celgene, Janssen, Novartis, Pfizer, Eli Lilly and Company, and UCB. R. Vender reports grants/research support from AbbVie, Amgen, Centocor, Dermira, Galderma, GSK, LEO Pharma, Eli Lilly and Company, Takeda, Novartis, Merck, Pfizer, UCB and Regeneron; he serves on the speakers bureaus of and received honoraria from AbbVie, Amgen, Janssen, Galderma, GSK, LEO Pharma, Novartis, Pfizer, Valeant, Actelion, Celgene, UCB, Pfizer, and Palladion; he reports consultancy fees from AbbVie, Amgen, Janssen, Galderma, GSK, LEO Pharma, Novartis, Pfizer, UCB, and Regeneron. C.-C. Wei reports consulting for Pfizer, Celgene, Chugai, UCB Pharma and TSH Taiwan; has received research grants from BMS, Janssen, Pfizer, Sanofi-Aventis, Novartis; and has served on speakers bureaus for Abbott, BMS, Chugai, Eisai, Janssen, and Pfizer. P. Nash received funding for research and clinical trials and honoraria for advice and lectures on behalf of Pfizer, Roche, UCB, MSD, BMS, Novartis, Eli Lilly and Company, AbbVie, and Janssen. J. Birt, D.H. Adams, O. Benichou, and C.-Y. Lin are full-time employees of Eli Lilly and Company and own stock.

**Introduction**
Psoriatic arthritis (PsA) is a progressive, destructive disease causing deformities, impaired physical function, loss of health-related quality of life (HRQOL), and increased mortality (1). This disease negatively impacts multiple physical and emotional aspects of patients’ lives (1-3). Patients with PsA reported poorer HRQOL relative to the general population and to patients with psoriasis (2, 4). Although patients with PsA and rheumatoid arthritis report reduced HRQOL, there are some differences on the impact of these conditions on HRQOL with the presence of psoriasis perhaps causing unique disabilities among patients with PsA (5).

The current standard of care for PsA includes non-steroidal anti-inflammatory drugs, glucocorticoids, conventional disease-modifying anti-rheumatic drugs (cDMARDs), and biologic agents such as tumour necrosis factor alpha inhibitors (TNFi) (6-8). TNFi are effective in reducing the signs and symptoms of PsA (6-9), but some patients may experience an inadequate response, and others may be intolerant. The success of TNFi has increased physician and patient expectations for new agents that can be used in patients that do not respond well to TNFi.

The interleukin-17 (IL-17) pathway is involved in normal and pathological function of the immune system and plays a role in inflammatory disorders such as psoriasis and PsA (10). This led to the development of IL-17A inhibitors for treatment of psoriasis and PsA. Proof-of-concept was demonstrated in successful phase 3 clinical trials in psoriasis or PsA involving the IL-17A inhibitors secukinumab (11-13), brodalumab (14), and ixekizumab (15-18).

Izekizumab is a high-affinity monoclonal antibody that selectively targets IL-17A (19). Izekizumab treatment improved the signs and symptoms in patients with active PsA who were biologic-naïve (SPIRIT-P1) (15) and in patients with an inadequate response or intolerance to TNFi (SPIRIT-P2) through 24 weeks (16). The objective of this study was to assess patient-reported outcomes (PROs) up to 52 weeks in ixekizumab-treated patients who had prior inadequate response or intolerance to TNFi from the SPIRIT-P2 trial (NCT 02349295).

**Materials and methods**

**Patients**
Detailed enrolment and exclusion criteria for SPIRIT-P2 were previously reported (16). Key enrolment criteria included age ≥18 years, active psoriatic skin lesions (plaque) or a documented history of plaque psoriasis, active PsA for ≥6 months and meeting the CIASSification criteria for Psoriatic Arthritis (CASPAR) (20), and ≥3 of 68 tender joint counts and of 66 swollen joint counts (16). Other key criteria were prior treatment with ≥1 cDMARD and 1 or 2 TNFi with either an inadequate response to at least 1 TNFi due to lack of efficacy or TNFi intolerance.

**Ethics**
SPIRIT-P2 was conducted in accordance with the standards of the responsible local committee or with the Helsinki Declaration of 1975/83. All patients provided written informed consent.

**Study design**
SPIRIT-P2 was a randomised, double-blind, placebo-controlled phase 3 trial (16). Patients were randomised 1:1:1 to ixekizumab 80 mg every 4 weeks (IXEQ4W), ixekizumab 80 mg every 2 weeks (IXEQ2W), or placebo (Supplementary Fig. 1). Patients receiving ixekizumab were given a 160-mg starting dose at Week 0. Randomisation was stratified by country and TNFi experience (inadequate response to 1 TNFi, inadequate response to 2 TNFi, or intolerance to TNFi).

Using predefined tender and swollen joint criteria, patients with an inadequate response at Week 16 were required to add or modify concomitant drugs (16). Inadequate responders who were originally assigned ixekizumab continued their originally assigned dose of ixekizumab, whereas patients initially assigned to placebo were re-randomised 1:1 to IXEQ2W or IXEQ4W. After Week 24, patients still receiving placebo at the completion of the double-blind treatment period were re-randomised 1:1 to either IXEQ4W or...
**IxEQ2W.** Patients receiving ixekizumab at Week 24 received the same dose during the study remainder. The data through Week 52 are reported.

**Assessments**

The PRO domains that are the focus of this report include assessment of disease activity (arthritis, axial symptoms, and skin), quality of life, and work productivity. Arthritis-related disease activity was assessed using a Joint Pain and a Patient Global Assessment (PtGA) 100-mm horizontal visual analogue scale (VAS) (21). Axial disease activity was assessed using the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI;0–10; higher score more severe) (22). The BASDAI was developed to assess axial spondyloarthritis (22) and is not specific for axial disease on HRQOL (29–31).

**Table I. Baseline demographics and characteristics*.**

<table>
<thead>
<tr>
<th></th>
<th>PBO N=118</th>
<th>IxEQ4W N=122</th>
<th>IxEQ2W N=123</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years, mean (SD)</td>
<td>51.5 (10.4)</td>
<td>52.6 (13.6)</td>
<td>51.7 (11.9)</td>
</tr>
<tr>
<td>Male, n (%)</td>
<td>56 (47.5)</td>
<td>63 (51.6)</td>
<td>50 (40.7)</td>
</tr>
<tr>
<td>Weight, kg, mean (SD)</td>
<td>91.0 (22.1)</td>
<td>89.9 (22.0)</td>
<td>85.2 (20.7)</td>
</tr>
<tr>
<td>BMI (kg/m²), mean (SD)</td>
<td>31.6 (7.6)</td>
<td>30.9 (7.1)</td>
<td>30.1 (6.8)</td>
</tr>
<tr>
<td><strong>Race, n (%)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Asian</td>
<td>7 (5.9)</td>
<td>7 (5.7)</td>
<td>7 (5.7)</td>
</tr>
<tr>
<td>Black or African American</td>
<td>1 (0.8)</td>
<td>1 (0.8)</td>
<td>1 (0.8)</td>
</tr>
<tr>
<td>White</td>
<td>108 (91.5)</td>
<td>111 (91.0)</td>
<td>113 (92.6)</td>
</tr>
<tr>
<td>Multiple or other</td>
<td>2 (1.7)</td>
<td>3 (2.4)</td>
<td>1 (0.8)</td>
</tr>
<tr>
<td><strong>Previous TNFi treatment, n (%)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inadequate response to 1</td>
<td>68 (57.6)</td>
<td>71 (58.2)</td>
<td>65 (52.8)</td>
</tr>
<tr>
<td>Inadequate response to 2</td>
<td>41 (34.7)</td>
<td>41 (33.6)</td>
<td>46 (37.4)</td>
</tr>
<tr>
<td>Intolerance</td>
<td>9 (7.6)</td>
<td>10 (8.2)</td>
<td>12 (9.8)</td>
</tr>
<tr>
<td><strong>Current MTX use, n (%)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Current cDMARD use, n (%)</td>
<td>52 (44.1)</td>
<td>60 (49.2)</td>
<td>73 (59.3)</td>
</tr>
<tr>
<td>Time since PsA diagnosis, years, mean (SD)</td>
<td>9.2 (7.3)</td>
<td>11.0 (9.6)</td>
<td>9.9 (7.4)</td>
</tr>
<tr>
<td>Tender joint count (68 joints), mean (SD)</td>
<td>23.0 (16.2)</td>
<td>22.0 (14.1)</td>
<td>25.0 (17.3)</td>
</tr>
<tr>
<td>Swollen joint count (66 joints), mean (SD)</td>
<td>10.3 (7.4)</td>
<td>13.1 (11.2)</td>
<td>3.5 (11.5)</td>
</tr>
<tr>
<td>Patients with current psoriasis, n (%)</td>
<td>108 (91.5)</td>
<td>118 (96.7)</td>
<td>113 (91.9)</td>
</tr>
<tr>
<td>% Body surface area ≥3%, n (%)¶</td>
<td>67 (62.6)</td>
<td>68 (61.8)</td>
<td>68 (63.0)</td>
</tr>
<tr>
<td><strong>PASI score, mean (SD)</strong></td>
<td>7.1 (7.1)</td>
<td>9.3 (9.1)</td>
<td>8.8 (10.3)</td>
</tr>
<tr>
<td>SF-36 PCS, mean (SD)</td>
<td>33.9 (9.0)</td>
<td>34.8 (8.8)</td>
<td>34.3 (9.1)</td>
</tr>
<tr>
<td>SF-36 MCS, mean (SD)</td>
<td>48.0 (13.1)</td>
<td>49.6 (11.3)</td>
<td>49.1 (11.5)</td>
</tr>
<tr>
<td><strong>SF-36 domain scores, mean (SD)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Physical functioning</td>
<td>41.2 (26.0)</td>
<td>43.2 (26.7)</td>
<td>44.8 (26.4)</td>
</tr>
<tr>
<td>Role physical</td>
<td>41.6 (24.1)</td>
<td>47.4 (25.7)</td>
<td>42.9 (26.3)</td>
</tr>
<tr>
<td>Bodily pain</td>
<td>37.1 (19.0)</td>
<td>39.5 (20.1)</td>
<td>37.2 (19.5)</td>
</tr>
<tr>
<td>General health</td>
<td>45.3 (19.8)</td>
<td>46.8 (20.3)</td>
<td>45.2 (19.9)</td>
</tr>
<tr>
<td>Vitality</td>
<td>36.9 (21.9)</td>
<td>38.8 (21.2)</td>
<td>39.9 (22.0)</td>
</tr>
<tr>
<td>Social functioning</td>
<td>62.6 (29.1)</td>
<td>67.1 (27.5)</td>
<td>65.5 (27.2)</td>
</tr>
<tr>
<td>Role emotional</td>
<td>72.0 (29.6)</td>
<td>75.6 (26.6)</td>
<td>73.3 (26.7)</td>
</tr>
<tr>
<td>Mental health</td>
<td>66.1 (22.6)</td>
<td>69.0 (21.0)</td>
<td>68.0 (20.6)</td>
</tr>
<tr>
<td><strong>EQ-5D VAS, mean (SD)</strong></td>
<td>53.6 (20.0)</td>
<td>53.9 (22.4)</td>
<td>53.9 (19.7)</td>
</tr>
<tr>
<td>Joint pain VAS, mean (SD)</td>
<td>63.9 (20.1)</td>
<td>63.9 (21.4)</td>
<td>62.7 (20.9)</td>
</tr>
<tr>
<td>PtGA VAS, mean (SD)</td>
<td>64.1 (21.5)</td>
<td>66.4 (20.5)</td>
<td>66.0 (20.5)</td>
</tr>
<tr>
<td>BASDAI, mean (SD)</td>
<td>6.8 (1.4)</td>
<td>6.5 (1.4)</td>
<td>6.6 (1.4)</td>
</tr>
<tr>
<td>BASDAI—neck, back, or hip pain, mean (SD)**</td>
<td>7.3 (1.5)</td>
<td>7.2 (1.4)</td>
<td>7.2 (1.4)</td>
</tr>
<tr>
<td><strong>WPAS-HIP, mean (SD)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>% absenteeism, mean (SD)</td>
<td>11.9 (28.1)</td>
<td>11.6 (26.6)</td>
<td>8.8 (23.2)</td>
</tr>
<tr>
<td>% presenteeism, mean (SD)</td>
<td>40.4 (28.8)</td>
<td>45.0 (25.7)</td>
<td>36.9 (25.0)</td>
</tr>
<tr>
<td>% overall work impairment, mean (SD)</td>
<td>41.5 (29.6)</td>
<td>46.9 (26.7)</td>
<td>38.8 (26.6)</td>
</tr>
<tr>
<td>% activity impairment, mean (SD)</td>
<td>54.0 (25.8)</td>
<td>53.9 (24.9)</td>
<td>49.3 (26.5)</td>
</tr>
<tr>
<td><strong>DLQI, mean (SD)</strong></td>
<td>9.6 (8.1)</td>
<td>9.1 (7.4)</td>
<td>9.2 (7.8)</td>
</tr>
<tr>
<td>Itch NRS, mean (SD)</td>
<td>5.7 (2.8)</td>
<td>5.5 (2.5)</td>
<td>5.6 (3.0)</td>
</tr>
</tbody>
</table>

*Some data from Nash et al. (16).

*Among patients with plaque psoriasis.

*Evaluated among ITT patients with psoriatic lesions involving ≥3% of the body surface area. N=67, N=68, and N=68 for PBO, IxEQ4W, and IxEQ2W, respectively.

*Evaluated among ITT patients with baseline BASDAI ≥4. N=96, N=100, and N=99 for PBO, IXEQ4W, and IxEQ2W, respectively.

**Among patients with baseline BASDAI Individual Component #2 (neck, back, or hip pain) score ≥4.

BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; BMI: body mass index; cDMARD: conventional disease-modifying anti-rheumatic drugs; DLQI: Dermatology Life Quality Index; EQ-5D: European Quality of Life–5 Dimensions 5 Level; ITT: intent-to-treat; IxEQ2W: ixekizumab 80 mg every 2 weeks; IxEQ4W: ixekizumab 80 mg every 4 weeks; MCS: Mental Component Summary; MTX: methotrexate; N: population size; n: number in group; NRS: Numeric Rating Scale; PASI: Psoriasis Area Severity Index; PtGA: placebo; PCS: Physical Component Summary; PsA: psoriatic arthritis; PtGA: Patient Global Assessment of Disease Activity; SD: standard deviation; SF-36: 36-Item Short Form Health Survey; TNFi: tumour necrosis factor inhibitor; VAS: visual analogue scale; WPAS-HIP: Work Productivity and Activity Impairment–Specific Health Problem.**
were not collected after Week 24 for the DLQI. Some data to Week 24 (Joint Pain VAS, PGAVA VAS, SF-36 PCS, SF-36 MCS) were previously reported in the SPIRIT-P2 primary analysis (16) and are presented here for completeness, in addition to previously unreported Week 52 data.

**Statistics**

Health outcomes were analysed using the intention-to-treat (ITT) population, defined as all randomly assigned patients. Skin-specific PROs (e.g. itch NRS, DLQI) were assessed in the subset of patients with ≥3% body surface area (BSA) at baseline affected by psoriasis. During the first 24 weeks, categorical data were analysed using a logistic regression model adjusting for geographical region, and previous TNFi use (inadequate responder to 1 TNFi, intolerance to a TNFi). Fisher’s exact test was used for secondary comparisons. For categorical analyses, patients with missing data at Week 24 or those deemed Week 16 inadequate responders, or those who discontinued treatment on or prior to Week 24 were imputed as non-responders.

For the first 24 weeks, changes in continuous data were analysed using a mixed models repeated measures analysis (MMRM). This model used treatment, visit, geographical region, previous TNFi, treatment-by-visit interaction, geographical region-by-visit interaction, and TNFi use-by-visit interaction as factors and with baseline and baseline value-by-visit interactions as continuous, fixed covariates. For patients classified as Week 16 inadequate responders, data after Week 16 were not included. Data are expressed as least squares mean (LSM) change from baseline. Mean SF-36 domain scores were presented using spydergrams and the missing data were imputed using the modified baseline observation carried forward method. The study was only designed and powered to compare the ixekizumab treatment groups with placebo, not the ixekizumab groups with each other.

For Week 52 data, post-hoc analyses were conducted; these were based on patients who were randomised to ixekizumab treatment at study initiation. The multiple imputation method was used to impute missing data. Using this method, missing observations are imputed multiple times (m-times), and the final estimate is calculated after pooling information from these m-imputed datasets. Observed data for Week 16
inadequate responders were included in the analysis. For comparison with Week 52, data from Week 12 and 24 were also calculated using multiple imputation.

Results

Patients and baseline demographics

The ITT population was comprised of 363 patients (118 placebo; 122 IXEQ4W; 123 IXEQ2W) (16). Between-arm baseline characteristics were mostly similar except current methotrexate use and swollen joint counts, which were all higher in the IXEQ2W group (Table I).

Disease activity

Ixekizumab-treated patients reported significant improvement relative to placebo in both the joint pain VAS and the PtGA VAS through Week 24 (Supplementary Table I) (16), persisting through Week 52 (Table II). Among the subgroup of ITT patients with baseline BASDAI >4, ixekizumab-treated patients reported significant improvements in their BASDAI total score.

Fig. 1. Dermatology Life Quality Index and Itch.
The graphs show a subset of the ITT population consisting of patients with psoriatic arthritis and psoriatic skin lesions affecting ≥3% BSA at baseline. A, LSM change from baseline in DLQI to Week 24; B, Percentage of patients reporting DLQI = 0.1 to Week 24 C, LS mean change from baseline in Itch NRS to Week 24; D, Percentage of patients reporting Itch NRS = 0 to Week 24.

* p≤0.001 active vs. PBO; † p≤0.005 active vs. PBO; ¥ p≤0.05 active vs. PBO.

In Panel A and C, baseline was the last non-missing value on or before the date of first injection of study treatment at Week 0. Observed data at Weeks 20 and 24 for Week 16 inadequate responders were excluded. The p-values are from an MMRM model.

In Panels B and D, NRI was applied for inadequate responders at Week 16 and patients who discontinued on or before Week 24. Observed data after at Weeks 20 and 24 for Week 16 inadequate responders were excluded. p-values are from logistic model or Fisher’s exact test.

BSA, body surface area; DLQI, Dermatology Life Quality Index; ITT, intent-to-treat; IXEQ2W, ixekizumab 80 mg every 2 weeks; IXEQ4W, ixekizumab 80 mg every 4 weeks; LSM, least squares mean; MMRM: mixed models repeated measures analysis; N: population size; NRI: non-responder imputation; NRS: numeric rating scale; PBO: placebo.

Fig. 2. SF-36. The spydergrams depict mean SF-36 scores in the ITT population during the Placebo-controlled Period (baseline and Week 24) compared with age- and gender-matched normative values. mBOCF was applied for inadequate responders at Week 16 and patients who discontinued at or before Week 24.

BP: bodily pain; GH, general health; ITT: intent-to-treat; IXEQ2W: ixekizumab 80 mg every 2 weeks; IXEQ4W: ixekizumab 80 mg every 4 weeks; mBOCF: modified baseline observation carried forward; MH: mental health; Norm: normative value; PF: physical functioning; RE: role emotional; RP: role physical; SF: social functioning; SF-36: 36-Item Short Form Health Survey version 2; VT: vitality; W24: Week 24.
relative to placebo through Week 24 (Supplementary Table I; Supplementary Fig. 2), persisting through Week 52 (Table II). In the subset of patients with a score >4 for question 2 of the BASDAI (neck, back, or hip pain), the ixekizumab groups reported significantly improved neck, back, and hip pain at Week 12 and 24 relative to placebo (Supplementary Table I), persisting through Week 52 (Table II).

Skin-related PROs
Among patients with baseline BSA ≥3%, ixekizumab-treated patients reported significant improvement in the DLQI compared to those treated with placebo as early as Week 2 through Week 24 (Fig. 1A; Supplementary Table I). Likewise, higher proportions of ixekizumab-treated patients reported a DLQI of 0 or 1, indicating skin symptoms had no impact on patient quality of life, through Week 24 (Fig. 1B; Supplementary Table I). Patients did not complete the DLQI after Week 24. Concomitant with improvements in DLQI, ixekizumab-treated patients with baseline BSA ≥3% reported statistically significant improvement in itch compared to that reported by the placebo group though Week 24 (Fig. 1C; Supplementary Table I). Improvement persisted through Week 52 (Table II). Likewise, higher proportions of patients in the ixekizumab groups compared to the placebo group reported no itch through Week 24 (Fig. 1D; Supplementary Table I), persisting through Week 52 (Table II).

Quality of life
Patients in the ixekizumab groups reported significant improvements relative to those in the placebo group in SF-36 PCS and SF-36 MCS at Week 12 and 24 (Supplementary Table I) (16), persisting through Week 52 (Table II) (34). Likewise, patients reported statistically significant improvement relative to placebo in all SF-36 domain scores at Week 12 and 24 (Supplementary Table I), persisting through Week 52 (Table II). Figure 2 shows mean SF-36 domain scores at baseline and Week 24 relative to age-and gender-matched normative scores. At baseline, patients had SF-36 domain scores below age- and gender-matched normative scores. By Week 24, all domains had improved versus baseline with both ixekizumab dosing regimens but not with placebo (Fig. 2). Consistent with the SF-36 results, ixekizumab-treated patients reported significant improvement in their EQ-5D 5L VAS scores through Week 24, achieving maximal improvement by Week 8 (Fig. 3). Improvement persisted through Week 52 (Table II).

Work productivity
Ixekizumab-treated patients reported significant improvement in 3 of 4 WPAL-SHP domains (presenteeism, activity impairment, and work impairment) through Week 24 (Fig. 4; Supplementary Table I). Improvement persisted to Week 52 (Table II).

Discussion
Previous results from the SPIRIT-P2 study demonstrated that treatment with ixekizumab provided clinically meaningful and sustained (up to 52 weeks) improvements in joint, skin, and physical function in active PsA patients with prior inadequate response or intolerance to TNFi (16, 34). These analyses extend the findings by reporting on the patient-reported benefit across a broad range of outcome domains. As previously reported, ixekizumab-treated patients had significantly greater improvements in patient-reported pain, global disease activity, and generic measures of HRQOL (i.e., SF-36 PCS and MCS) at Week 24 when compared with that of the placebo group in SPIRIT-P2 (16). This report expands the assessment of HRQOL showing statistically significant improvement in ixekizumab-treated patients when compared with that of placebo in all 8 domains of the SF-36 at Week 24. The domains of Physical Functioning, Role Physical, Bodily Pain, and General Health were the most impacted (i.e., lowest scores) compared to age- and gender-matched norms at baseline. At Week 24, the domains showing the largest improvement (at least 15 points in both treatment groups) after ixekizumab treatment were Physical Functioning, Role Physical, Bodily Pain, and Social Functioning. Statistically significant improvement was also seen in the other SF-36 domains, which include those more mental/emotionally-related; this could be related to improvement of skin symptoms, as psoriasis improve...
ment has been shown in other studies to have a greater impact on the mental-related scores (35). Complementary results were also seen with the EQ-5D VAS.

Improvement related to skin symptoms was demonstrated by patient-reported benefit as measured by the Itch NRS and DLQI. Almost one-quarter of the ixekizumab-treated patients (placebo = 0%) reported complete resolution of itch symptoms at Week 24. Improvement in overall skin symptoms translated to HRQOL benefit with approximately 50% of patients treated with ixekizumab reporting a DLQI of 0 or 1 at Week 24, compared with 9% in the placebo group. In patients with PsA, optimal improvements in HRQOL are dependent on successful treatment of both joint and skin symptoms (36). In post-hoc analyses, the subgroup of patients with neck, back, or hip pain at baseline (score of ≥4 on question 2 of the BASDAI), reported significant improvements relative to placebo in neck, back, or hip pain at Week 24, suggesting that ixekizumab may also work on axial symptoms of PsA. However, this is a non-specific assessment, so a definitive conclusion can only come from ongoing axial spondyloarthritides trials comparing ixekizumab to placebo.

As spondyloarthropathies including PsA commonly affect individuals during their prime working years, work disability is an important functional outcome (37). Data from the Multinational Assessment of Psoriasis and Psoriatic Arthritis survey (conducted between June and August 2012) of 712 patients with PsA identified that 32% of patients reported missing work during the past year from their disease, another 32% reported that PsA impacted their ability to work full-time, and approximately 25% reported that PsA impacted their ability to get a job, keep a job, or their career choice (38). In the SPIRIT-P2 study, patients reported considerable work and activity impairment at baseline. At Week 24, ixekizumab-treated patients reported statistically significant improvement in work activities (presenteeism and work impairment), as well as activities outside of work (activity impairment), relative to that reported by placebo-treated patients. Absenteeism did not improve in patients treated with ixekizumab versus those treated with placebo, possibly due to the low baseline scores and low number of patients with non-zero absenteeism. Improvement in work productivity is important because in addition to direct medical costs, the financial (and psychosocial) burden of PsA is shared by patients’ employers, patients’ families, and society in terms of costs related to impaired ability to perform both paid work and unpaid work (such as participating in household chores).

In this study, the clinically meaningful improvement in PROs seen during ixekizumab treatment at Week 24, including global disease activity, pain, itch, axial symptoms, generic and skin-specific measures of HRQOL, and work productivity were also sustained or improved further at Week 52. Improvements in PROs seen with ixekizumab treatment in the SPIRIT-P2 trial are similar, and in some cases higher, than those reported in the biologic-naïve population from SPIRIT-P1 (15). In other studies that have made the comparison between biologic-naïve
and TNF-experienced using a biologic agent, some have shown a similar treatment effect on PROs between patient populations naïve to versus experienced with TNFi (39), whereas others have shown that patients with prior inadequate response to TNFi had relatively smaller improvements in PROs relative to patients naïve to TNFi therapies (40, 41).

Limitations of this study include that it was not powered to detect differences between the IXEQ4W and IXEQ2W groups, although the doses seem to provide comparable efficacy. Additionally, there was no placebo comparator after Week 24. The trial results cannot be generalised beyond the patient population studied in the trial.

In conclusion, treatment with ixekizumab up to 52 weeks improved patient-reported measures of disease activity, generic and skin-specific HRQOL, and work impact of PsA on productivity in patients with active PsA and a prior history of TNFi therapy. These improvements in PROs were comparable to those seen in biologic-naïve patients from the SPIRIT-P1 trial (15).

Acknowledgement

Writing assistance on behalf of Eli Lilly and Company was provided by Lori Kornberg, PhD, who is a full-time employee of Syneos Health, Raleigh, NC.

References

Ixekizumab improves patient-reported outcomes / A. Kavanaugh et al.